Within the tumor microenvironment, AB21 monotherapy and combination therapy with anti-PD-1 caused a slight reduction in CD11c+MHC-II+ DCs; however, DC production of IL-12, a marker of activated DCs and a potent proinflammatory cytokine necessary for tumor control in response to ICIs [37], was significantly increased in response to combination therapy but not AB21 or anti-PD-1 monotherapy (Fig. 6f). The gene discussed is ITGAX; the disease is neoplasm.